GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing to raise £1.25 million

25 Jan 2011 07:00

RNS Number : 9952Z
ViaLogy PLC
25 January 2011
 



 

ViaLogy PLC ("ViaLogy" or "the Company")

Placing to raise £1.25 million

London, January 25, 2011. ViaLogy (LSE:VIY) is pleased to announce that it has today raised £1.25 million through the placing of 41,666,664 new ordinary shares of 1p each ("Placing Shares") at a price of 3p per share with certain existing shareholders ("the Placing").

The net proceeds of the Placing will be used in the further expansion of ViaLogy's energy business which uses its proprietary QuantumRD™ technology to discover and characterise hydrocarbon reservoirs and generate drilling targets.

Application has been made for the 41,666,664 Placing Shares to be admitted to trading on AIM and dealings are expected to commence on 31 January 2011. Following the Placing, the total number of ordinary shares in issue and therefore the total number of voting rights is 733,941,998.

Terry Bond, chairman of ViaLogy commented: "This funding will help to provide a firm financial base during what promises to be a very important year for the company. At the beginning of 2010, and with our previous series of successful wells in Texas as a launching pad, the board took a deliberate decision to focus our attention on global E&P companies as the path to establish QuantumRD, a novel realisation of seismic interferometry, as a standard industry platform. This, we believe, is where the commercial future of our company lies.

"The new funds will permit some expansion of our capacity to meet anticipated contract demand for new offshore prospects in the near term. As previously announced, we have made significant progress in the past twelve months in gaining the acceptance of a new technology in the upstream E&P sector. We concluded a Master Services contract with a supermajor and are working on our first project for them; in addition, following successful completion of a technology demonstration project, we are in advanced talks with a Fortune Global 100 international E&P firm. Other talks are underway with a non-US national oil company. The discussions focus on large core projects, both onshore and offshore, which we expect will lead to commercial contracts. We have also received enquiries from some of the large international oilfield services firms, and we are in advanced discussions with one of them in relation to a possible strategic partnership." 

Options Grant

Under the terms of his employment contract entered into on June 22nd, 2010, Dr. Sandeep Gulati, ViaLogy's founder and Chief Technology Officer, is entitled to additional options awards in order to retain his interest in the ordinary share capital of ViaLogy. The Company has therefore issued 3,967,360 options exercisable at 1p per share. 

For further information please contact:

 

ViaLogy PLC 

 

 

 

 

 

Terry Bond, Chairman - UK & Europe

 

+44 (0) 1235 834734

 

 

 

 

 

 

Seymour Pierce Limited

Nominated Advisor and Broker to ViaLogy

 

 

 

 

 

Mark Percy / Catherine Leftley

(Corporate Finance)

Katie Ratner/Jeremy Stephenson

(Corporate Broking)

 

+44 (0) 207 107 8000

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUSSNRASAAUAR
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.